These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

279 related items for PubMed ID: 31302695

  • 41. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.
    Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, Petri MA, Ginzler EM, Chatham WW, McCune WJ, Fernandez V, Chevrier MR, Zhong ZJ, Freimuth WW.
    Arthritis Rheum; 2009 Sep 15; 61(9):1168-78. PubMed ID: 19714604
    [Abstract] [Full Text] [Related]

  • 42. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
    Loncharich MF, Anderson CW.
    ACR Open Rheumatol; 2022 Jun 15; 4(6):486-491. PubMed ID: 35157371
    [Abstract] [Full Text] [Related]

  • 43. Long-term safety and efficacy of belimumab in Japanese patients with SLE: A 7-year open-label continuation study.
    Tanaka Y, Curtis P, DeRose K, Kurrasch R, Kinoshita K, Tanaka R, Yamazaki Y, Roth DA.
    Mod Rheumatol; 2023 Jan 03; 33(1):122-133. PubMed ID: 34915574
    [Abstract] [Full Text] [Related]

  • 44. Safety and efficacy of belimumab after B cell depletion therapy in systemic LUPUS erythematosus (BEAT-LUPUS) trial: statistical analysis plan.
    Muller P, Chowdhury K, Gordon C, Ehrenstein MR, Doré CJ.
    Trials; 2020 Jul 16; 21(1):652. PubMed ID: 32677992
    [Abstract] [Full Text] [Related]

  • 45. Efficacy of belimumab in patients with systemic lupus erythematosus from North East Asia: Results of exploratory subgroup analyses.
    Zheng J, Gu J, Su Y, Li Y, Li X, Xiong C, Cao H, Quasny H, Chu M, Curtis P, DeRose K, Kurrasch R, Meizlik P, Roth DA, Zhang F.
    Mod Rheumatol; 2023 Jul 04; 33(4):751-757. PubMed ID: 36208293
    [Abstract] [Full Text] [Related]

  • 46. Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study.
    Fanouriakis A, Adamichou C, Koutsoviti S, Panopoulos S, Staveri C, Klagou A, Tsalapaki C, Pantazi L, Konsta S, Mavragani CP, Dimopoulou D, Ntali S, Katsikas G, Boki KA, Vassilopoulos D, Konstantopoulou P, Liossis SN, Elezoglou A, Tektonidou M, Sidiropoulos P, Erden A, Sfikakis PP, Bertsias G, Boumpas DT.
    Semin Arthritis Rheum; 2018 Dec 04; 48(3):467-474. PubMed ID: 29555348
    [Abstract] [Full Text] [Related]

  • 47. Evaluation of a novel autoinjector for subcutaneous self-administration of belimumab in systemic lupus erythematosus
.
    Sheikh SZ, Hammer AE, Fox NL, Groark J, Struemper H, Roth D, Gordon D.
    Int J Clin Pharmacol Ther; 2016 Nov 04; 54(11):914-922. PubMed ID: 27668697
    [Abstract] [Full Text] [Related]

  • 48. Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme.
    Maslen T, Bruce IN, D'Cruz D, Ianosev M, Bass DL, Wilkinson C, Roth DA.
    Lupus Sci Med; 2021 Feb 04; 8(1):. PubMed ID: 33568389
    [Abstract] [Full Text] [Related]

  • 49. Belimumab and antimalarials combined against renal flares in patients treated for extra-renal systemic lupus erythematosus: results from 4 phase III clinical trials.
    Gomez A, Jägerback S, Sjöwall C, Parodis I.
    Rheumatology (Oxford); 2024 Feb 01; 63(2):338-348. PubMed ID: 37228028
    [Abstract] [Full Text] [Related]

  • 50. Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus.
    Wallace DJ, Navarra S, Petri MA, Gallacher A, Thomas M, Furie R, Levy RA, van Vollenhoven RF, Cooper S, Zhong ZJ, Freimuth W, Cervera R, BLISS-52 and -76, and LBSL02 Study Groups.
    Lupus; 2013 Feb 01; 22(2):144-54. PubMed ID: 23213069
    [Abstract] [Full Text] [Related]

  • 51. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials.
    Manzi S, Sánchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, Ginzler EM, D'Cruz DP, Doria A, Cooper S, Zhong ZJ, Hough D, Freimuth W, Petri MA, BLISS-52 and BLISS-76 Study Groups.
    Ann Rheum Dis; 2012 Nov 01; 71(11):1833-8. PubMed ID: 22550315
    [Abstract] [Full Text] [Related]

  • 52. Belimumab: targeted therapy for lupus.
    Chugh PK, Kalra BS.
    Int J Rheum Dis; 2013 Feb 01; 16(1):4-13. PubMed ID: 23441766
    [Abstract] [Full Text] [Related]

  • 53. Belimumab: in systemic lupus erythematosus.
    Burness CB, McCormack PL.
    Drugs; 2011 Dec 24; 71(18):2435-44. PubMed ID: 22141386
    [Abstract] [Full Text] [Related]

  • 54. Clinical response trajectories and drug persistence in systemic lupus erythematosus patients on belimumab treatment: A real-life, multicentre observational study.
    Nikoloudaki M, Nikolopoulos D, Koutsoviti S, Flouri I, Kapsala N, Repa A, Katsimbri P, Theotikos E, Pitsigavdaki S, Pateromichelaki K, Bertsias A, Elezoglou A, Sidiropoulos P, Fanouriakis A, Boumpas D, Bertsias G.
    Front Immunol; 2022 Dec 24; 13():1074044. PubMed ID: 36685524
    [Abstract] [Full Text] [Related]

  • 55. Cumulative Corticosteroid Dose Over Fifty-Two Weeks in Patients With Systemic Lupus Erythematosus: Pooled Analyses From the Phase III Belimumab Trials.
    van Vollenhoven RF, Petri M, Wallace DJ, Roth DA, Molta CT, Hammer AE, Tang Y, Thompson A.
    Arthritis Rheumatol; 2016 Sep 24; 68(9):2184-92. PubMed ID: 26992106
    [Abstract] [Full Text] [Related]

  • 56. Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting.
    Gatto M, Saccon F, Zen M, Regola F, Fredi M, Andreoli L, Tincani A, Urban ML, Emmi G, Ceccarelli F, Conti F, Bortoluzzi A, Govoni M, Tani C, Mosca M, Ubiali T, Gerosa M, Bozzolo E, Canti V, Cardinaletti P, Gabrielli A, Tanti G, Gremese E, De Marchi G, De Vita S, Fasano S, Ciccia F, Pazzola G, Salvarani C, Negrini S, Puppo F, Di Matteo A, De Angelis R, Orsolini G, Rossini M, Faggioli P, Laria A, Piga M, Mathieu A, Scarpato S, Rossi FW, de Paulis A, Brunetta E, Ceribelli A, Selmi C, Prete M, Racanelli V, Vacca A, Bartoloni E, Gerli R, Larosa M, Iaccarino L, Doria A.
    Arthritis Rheumatol; 2020 Aug 24; 72(8):1314-1324. PubMed ID: 32275125
    [Abstract] [Full Text] [Related]

  • 57. The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis.
    Wilkinson C, Henderson RB, Jones-Leone AR, Flint SM, Lennon M, Levy RA, Ji B, Bass DL, Roth D.
    Arthritis Res Ther; 2020 May 04; 22(1):102. PubMed ID: 32366280
    [Abstract] [Full Text] [Related]

  • 58. Safety and efficacy of belimumab in older adults with SLE: results of an integrated analysis of clinical trial data.
    D'Cruz D, Eriksson G, Green Y, Hammer A, Ji B, Meizlik P, Roth DA.
    Lupus Sci Med; 2023 Mar 04; 10(1):. PubMed ID: 36963777
    [Abstract] [Full Text] [Related]

  • 59. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus.
    Stohl W, Hiepe F, Latinis KM, Thomas M, Scheinberg MA, Clarke A, Aranow C, Wellborne FR, Abud-Mendoza C, Hough DR, Pineda L, Migone TS, Zhong ZJ, Freimuth WW, Chatham WW, BLISS-52 Study Group, BLISS-76 Study Group.
    Arthritis Rheum; 2012 Jul 04; 64(7):2328-37. PubMed ID: 22275291
    [Abstract] [Full Text] [Related]

  • 60. A randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosus.
    Chatham W, Chadha A, Fettiplace J, Kleoudis C, Bass D, Roth D, Gordon D.
    Lupus; 2017 Dec 04; 26(14):1483-1490. PubMed ID: 28467293
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.